17.53 -0.05 (-0.28%)
After hours: 4:30PM EST
|Bid||17.55 x 1400|
|Ask||17.58 x 3200|
|Day's Range||17.31 - 17.93|
|52 Week Range||9.97 - 18.44|
|Beta (3Y Monthly)||0.86|
|PE Ratio (TTM)||26.01|
|Earnings Date||Nov 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.50|
NEW YORK , Nov. 14, 2019 /PRNewswire/ -- RadNet Inc. (NASD: RDNT) will replace Gannett Co. Inc. (NYSE: GCI) in the S&P SmallCap 600 effective prior to the open of trading on Wednesday, November 20 . S&P ...
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
RadNet (RDNT) delivered earnings and revenue surprises of -27.27% and 2.70%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Total Net Revenue (“Revenue”) increased 20.9% to $292.7 million in the third quarter of 2019 from $242.1 million in the third quarter of 2018Adjusted EBITDA(1) increased 7.7% to.
RadNet, Inc. (RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services today reported it has created a multifaceted partnership with Whiterabbit.ai utilizing artificial intelligence, other technologies and operational protocols to address solutions for breast cancer imaging. The two companies recently completed a pilot program in RadNet’s Delaware and Florida markets which combined the use of machine learning and patient outreach to bring women into RadNet facilities for their screening exams. The trial substantially increased patient compliance, improved operational protocols and drove a level of customer service more similar to other consumer-facing industries.
RadNet (RDNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LOS ANGELES, Oct. 31, 2019 -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
GREENVILLE, S.C., Sept. 24, 2019 /PRNewswire/ -- eRAD, a subsidiary of RadNet, Inc. (RDNT), a leading provider of standards-based, web-centric radiology image and data management solutions, announced today that Solis Mammography has deployed eRAD RIS in 65 centers across six states. As the nation's largest independent provider of breast screening and diagnostic services, Solis Mammography has sites in Pennsylvania, Arizona, Colorado, North Carolina, Ohio, and Texas—including freestanding mammography centers and hospital partnerships. It also serves the DC metropolitan area through its affiliated brand, Washington Radiology, a multi-modality medical imaging provider with a 70-year history of care.
LOS ANGELES, Sept. 24, 2019 -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of.
GREENVILLE, S.C., Sept. 10, 2019 /PRNewswire/ -- eRAD announced today that its healthcare communication platform, RADAR, sent more than 1.2 million secure messages in the month of July. RADAR was developed to facilitate faster communication between physicians—and to patients. It provides streamlined delivery, receipt, and confirmation of any type of healthcare communication—from patient reminders and surveys to critical test results and lab work for referring physicians.
Improves the ability to diagnose neurological conditions. NEWARK, Del., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Delaware Imaging Network (DIN), Delaware’s largest network of outpatient medical imaging centers, which is a division of RadNet, Inc. (RDNT), a national leader in providing high-quality, cost-effective, outpatient diagnostic imaging services, has added NeuroQuant, a FDA-cleared MRI software used in the assessment of neurological conditions, to brain imaging studies at all its centers that offer MRI services.
RadNet (RDNT) delivered earnings and revenue surprises of -16.67% and 6.56%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Revenue increased 18.3% to $289.1 million in the second quarter of 2019 from $244.4 million in the second quarter of 2018Adjusted EBITDA(1) increased 13.0% to $43.1 million.
RadNet, Inc. (RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services today reported it has created a division to further its efforts in Artificial Intelligence (“A.I.”). In conjunction with this, RadNet reports it has acquired the 75% that it did not already own of Nulogix, Inc., an early stage company focused on creating A.I. solutions for the radiology industry. RadNet’s newly created A.I. division will focus on developing, acquiring and investing in technologies that focus on image interpretation and radiology business processes. In addition to internally developing A.I. solutions through its newly acquired Nulogix team, RadNet will evaluate partnering, licensing and investing in A.I. solutions developed by others.